Chemomab Therapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $15.5M
- Price
- $2.12
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.42%
- Volume
- 114.2K
About
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Quick stats
Shares outstanding7.3M
Computed float5.6M
Float / shares75.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534248
Websitehttps://www.chemomab.com
AI Summary
AI-generated1/4
criticalbullishm and a
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Chemomab announced a definitive all-stock merger agreement with Scipher Medicine, creating a combined entity valued at $150 million prior to a concurrent $30 million private placement.
Upon closing expected by year-end, Chemomab shareholders will own approximately 32% of the new company, which will trade under the ticker 'SCIP' and focus on advancing nebokitug into a Phase 2 rheumatoid arthritis trial in H1 2027.
Q2 financial results showed a net loss of $2.2 million with cash decreasing to $6.7 million, extending standalone runway only into Q1 2027, underscoring the necessity of the transaction.
Red flags
- Standalone cash runway extends only to Q1 2027, necessitating the merger to avoid insolvency
- Warrants issued in private placement have an exercise price based on a $75M valuation, a 50% discount to the $150M pro forma equity value
- Chemomab shareholders will be diluted to a minority 32% stake, with control transferring to Scipher management